Kaleido Biosciences
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Kaleido Biosciences sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Kaleido Biosciences: 10 sponsored US clinical trials, none currently recruiting.
Kaleido Biosciences sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Early Cirrhosis, with 1 trials.
Top-decile sponsor footprint
Kaleido Biosciences ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
10 total, page 1 of 1
An Observational Clinical Study to Evaluate COVID-19 Symptoms in "Long Hauler" Patients Who Participated in K031-120 or K032-120
NCT04814914
A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function
NCT04486482
A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function
NCT04508413
A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19
NCT04414124
UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder
NCT03933410
VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms
NCT03944369
Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis
NCT03855956
A Clinical Study to Assess the Effect of Novel Glycans on Nitrogen Metabolism of the Gut in Healthy Subjects
NCT04603378
A Clinical Study to Assess the Effect of Increasing Intake Amounts of Two Novel Glycans on the Gut Microbiota of Healthy Subjects
NCT04619875
A Study to Evaluate the Effect of Diet on the Tolerability of FOS in Healthy Volunteers
NCT02628678
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Therapeutic Areas
How the Kaleido Biosciences early-phase archive is shaped
10 indexed studies, none listed as recruiting (0% open); 8 completed (80%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Early Cirrhosis (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Kaleido Biosciences: archived-pipeline peers nationwide
Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Kaleido Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 archived trials
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Kaleido Biosciences page
10 registered trials is a research-attention snapshot, not an endorsement of Kaleido Biosciences or any single study.
- None of Kaleido Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Early Cirrhosis is the condition Kaleido Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Early Cirrhosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kaleido Biosciences pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.